Related to Rosetta Genomics to Slash 35 Jobs to Focus on MDx Commercialization in the U.S.

• Wanbang to Advance D-Pharm’s Late-Stage Stroke Therapy in China
  
• PPD Acquires BioDuro to Further Expand Its Outsourcing Capabilities in China
  
• Merck Serono to Invest More than €150M in R&D Center in China
  
• Gilead and GlaxoSmithKline Divvy Up Commercialization of Viread® for HBV in Key Asian Countries
  
• Sinovac Expands Vaccine Capabilities with New JV
  
• Cambridge University and Chi-Med to Study Angiogenesis Effects of Chinese Medicinal Plants
  
• Meda In-Licenses Commercial Rights to EpiCept’s AML Therapy for $3M
  
• Rosetta Genomics to Receive $4.5M in a Registered Direct Offering
  
• LFB Licenses Thallion’s Early-Stage Candidate for Treating STEC Infections
  
• Beijing Pioneer to Provide Olink’s Duolink Product Line in China
  
• ICON and Tigermed Team Up to Facilitate Access to Chinese Patient Populations
  
• Charles River to Take Over Sino-U.S. CRO WuXi in Deal Worth $1.6B
  
• PPD Opens Vaccine Clinical Research Center in Taizhou, China
  
• Huya and China Medical City Sign Alliance to Exploit Country’s Promising Pharma Projects
  
• Icon Sets Up Additional Lab Facility in China
  
• Swedish Orphan Biovitrum and Dongbao Ink Deal for European and Chinese Markets
  
• Thermo Fisher Opens New Technology Center in Shanghai
  
• Enzo Takes First Step in Becoming National Provider of Predictive Diagnostics
  
• Sinovac Wins $1.8M Chinese Flu Vaccine Contract and Gets Anflu Sanctioned in Hong Kong
  
• Nycomed Takes Majority Stake in Chinese Pharma Firm Techpool Bio-Pharma